Dataset Information
Transient pharmacologic lowering of A? production prior to deposition results in sustained reduction of amyloid plaque pathology.
Ontology highlight
ABSTRACT: Background
Alzheimer's disease (AD) is the leading cause of dementia among the elderly. Disease modifying therapies targeting A? that are in development have been proposed to be more effective if treatment was initiated prior to significant accumulation of A? in the brain, but optimal timing of treatment initiation has not been clearly established in the clinic. We compared the efficacy of transient pharmacologic reduction of brain A? with a ?-secretase inhibitor (GSI ) for 1-3 months (M) treatment windows in APP Tg2576 mice and subsequent aging of the mice to either 15M or 18M.Results
These data show that reducing A? production in a 2-3M windows both initiated and discontinued before detectable A? deposition has the most significant impact on A? loads up to 11M after treatment discontinuation. In contrast, initiation of treatment for 3M windows from 7-10M or 12-15M shows progressively decreasing efficacy.Conclusions
These data have major implications for clinical testing of therapeutics aimed at lowering A? production, indicating that; i) these therapies may have little efficacy unless tested as prophylactics or in the earliest preclinical stage of AD where there is no or minimal A? accumulation and ii) lowering A? production transiently during a critical pre-deposition window potentially provides long-lasting efficacy after discontinuation of the treatment.
SUBMITTER: Das P
PROVIDER: S-EPMC3477045 | biostudies-literature | 2012 Aug
REPOSITORIES: biostudies-literature
Publications
Transient pharmacologic lowering of Aβ production prior to deposition results in sustained reduction of amyloid plaque pathology.
Molecular neurodegeneration 20120814
<h4>Background</h4>Alzheimer's disease (AD) is the leading cause of dementia among the elderly. Disease modifying therapies targeting Aβ that are in development have been proposed to be more effective if treatment was initiated prior to significant accumulation of Aβ in the brain, but optimal timing of treatment initiation has not been clearly established in the clinic. We compared the efficacy of transient pharmacologic reduction of brain Aβ with a γ-secretase inhibitor (GSI ) for 1-3 months (M ...[more]
